TMDX

TMDX

USD

TransMedics Group Inc. Common Stock

$121.176+0.866 (0.719%)

リアルタイム価格

Healthcare
医療機器
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$120.310

高値

$125.220

安値

$119.000

出来高

1.03M

企業ファンダメンタルズ

時価総額

4.1B

業種

医療機器

United States

取引統計

平均出来高

1.00M

取引所

NGM

通貨

USD

52週レンジ

安値 $55現在値 $121.176高値 $145.5

関連ニュース

PR Newswire

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

もっと見る
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Analyst Upgrades

Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $147

Canaccord Genuity analyst William Plovanic maintains TransMedics Group with a Buy and raises the price target from $142 to $147.

もっと見る
Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $147
Analyst Upgrades

Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $140

Piper Sandler analyst Matt O'Brien maintains TransMedics Group with a Overweight and lowers the price target from $145 to $140.

もっと見る
Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $140
Analyst Upgrades

Needham Upgrades TransMedics Group to Buy, Announces $148 Price Target

Needham analyst Mike Matson upgrades TransMedics Group from Hold to Buy and announces $148 price target.

もっと見る
Needham Upgrades TransMedics Group to Buy, Announces $148 Price Target
Analyst Upgrades

Canaccord Genuity Maintains Buy on TransMedics Group, Maintains $142 Price Target

Canaccord Genuity analyst William Plovanic maintains TransMedics Group with a Buy and maintains $142 price target.

もっと見る
Canaccord Genuity Maintains Buy on TransMedics Group, Maintains $142 Price Target
Analyst Upgrades

Jefferies Initiates Coverage On TransMedics Group with Buy Rating, Announces Price Target of $145

Jefferies analyst Young Li initiates coverage on TransMedics Group with a Buy rating and announces Price Target of $145.